A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
Public ClinicalTrials.gov record NCT01026727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Multicenter, Randomized, Open Label, Comparative Trial of MPC-4326 in Combination With a Two to Three Drug Optimized Background Regimen Versus an Optimized, Three to Four Drug Antiretroviral Regimen for the Treatment of Triple Class Antiretroviral Experienced, HIV-1 Infected Subjects Failing Current Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase 2b study is designed to assess the long-term efficacy (24 weeks) of MPC-4326 in combination with a 2-3 drug optimized background regimen (OBR) relative to the efficacy of a 3-4 antiretroviral (ARV) regimen in treatment experienced, HIV-1 infected subjects.
Study identification
- NCT ID
- NCT01026727
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 2 participants
Conditions and interventions
Conditions
Interventions
- MPC-4326 plus a 2-3 drug optimized background regimen (OBR) Drug
- 3-4 commercially available antiretroviral drugs Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2009 (Type not available)
- Primary completion
- Jun 2010 (Actual)
- Completion
- Jun 2010 (Actual)
- Last update posted
- Jun 14, 2010
2009 – 2010
United States locations
- U.S. sites
- 21
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AIDS Healthcare Foundation Research Center | Beverly Hills | California | 90211 | — |
| Peter Wolfe, MD, PC | Los Angeles | California | 90036 | — |
| Quest Clinical Research | San Francisco | California | 94115 | — |
| Whitman Walker Clinic | Washington D.C. | District of Columbia | 20009 | — |
| Therafirst Medical Center | Fort Lauderdale | Florida | 33308 | — |
| Gary J. Richmond, MD, PA | Fort Lauderdale | Florida | 33316 | — |
| Wohlfeiler, Piperato and Associates, LLC | Miami Beach | Florida | 33139 | — |
| Orlando Immunology Center | Orlando | Florida | 32803-1851 | — |
| AIDS Research Consortium of Atlanta | Atlanta | Georgia | 30308 | — |
| Community Research Initiative of New England | Boston | Massachusetts | 2215 | — |
| University of Rochester , Strong Memorial Hospital | Rochester | New York | 14642 | — |
| North Bronx Health Care Network | The Bronx | New York | 10461 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Kaiser Permanente Immune Deficiency Clinic | Portland | Oregon | 97227 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| Southwest Infectious Disease | Dallas | Texas | 75204 | — |
| North Texas Infectious Disease Consultants, PA | Dallas | Texas | 75246 | — |
| Therapeutic Concepts, P.A | Houston | Texas | 77004 | — |
| DCOL Center | Longview | Texas | 75605 | — |
| CARE-ID | Annandale | Virginia | 22003 | — |
| EHS Pulmonary & Critical Care | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01026727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2010 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01026727 live on ClinicalTrials.gov.